Todos begins Phase 2 trial of Tollovir for hospitalized COVID patients


First 10 patients administered in 77 patients placebo controlled, randomized Phase 1 trial at Jerusalem’s Shaare Zedek Medical Center

With COVID-19 cases reaching to all new heights almost every day globally, Israel-based medical diagnostics and related solutions firm, Todos Medical, Ltd., has lately announced the commencement of a double blind, randomized, placebo-controlled Phase 2 trial of its antiviral NLC-V-01, Tollovir.

For the uninitiated, Tollovir is a patent-awaited therapeutic agent which is being created via a JV between Todos Medical and NLC Pharma. Apparently, it is a potent 3CL protease inhibitor which is being massively used for the treatment of hospitalized coronavirus patients.

As per company reports, the trial is being conducted at Shaare Zedek Medical Center in Jerusalem and is expected to evaluate the efficiency and safety of the drug for the novel COVID-19 in hospitalized patients.

Speaking on the Phase 2 trial, Co-Founder and Chief Scientific Officer at NLC Pharma, Dr. Dorit Arad cited that the launch of this Clinical trials comes out as an important step towards the clinical validation of the firm’s proprietary scientific work.

Dr. Dorit added that he is thrilled to know that his study on 3CL protease inhibitor, which is supported with data from Tel Aviv University and recognized by prominent pharmaceutical companies, is being used in the war against COVID-19.

In fact, as per Dr. Dorit Arad, Tollovir stands out to be justified as a potential clinical therapeutic for considerably reducing the severity of the coronavirus infection, while also helping in combating the risk of getting COVID-19 upon SARS-CoV-2 exposure.

On the other hand, President and CEO of Todos, Gerald E. Commissiong, quoted that the company is excited to initiate the Phase 2 clinical trial for Tollovir amidst the skyrocketing COVID-19 cases worldwide.

Gerald mentioned that Todos is proud to support Dr. Arad’s study of this drug candidate at a time when emerging variants are potentially challenging the progress made in the field of coronavirus in the previous year.

Source Credit: